source
- Lilly adds $870M to Gate Bioscience partnership to pursue new drug targetsEli Lilly is expanding its collaboration with Gate Bioscience, adding a new financial commitment of more than $870 million. The original July 2025 agreement gave Lilly access to Gate’s "Molecular…
- Viking Therapeutics jumps 24% after Phase 1 obesity data, Longeveron falls 64% on mid-stage setbackIn September biotech stocks showed wide swings, with Viking Therapeutics gaining 24% and Longeveron dropping 64% as investors reacted to clinical data and trial setbacks. Viking reported Phase 1 r…